Renal elimination of sclerostin increases with declining kidney function

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages 248-255

  Cejka, Daniel ^a   Marculescu, Rodrig ^a   Kozakowski, Nicolas ^a,b   Plischke, Max ^a   Reiter, Thomas ^a   Gessl, Alois ^a   Haas, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Clinical Institute of Pathology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; CALCIUM; CREATININE; PARATHYROID HORMONE; PHOSPHORUS; SCLEROSTIN; VITAMIN D;

ADULT; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; URINARY EXCRETION;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; UP-REGULATION; YOUNG ADULT;

EID: 84892181516     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2786     Document Type: Article

References (29)

1. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202-1209.
2. Brunkow ME, Gardner JC, Kovacevich BR, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589.
3. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-97.
4. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study. J Bone Miner Res. 2012;27:2592-2602.
5. Arasu A, Cawthon PM, Lui LY, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012; 97(6):2027-2032.
6. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24:578-588.
7. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948-959.
8. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
9. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):819-823.
10. Cejka D, Jager-Lansky A, Kieweg H, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2011;27(1): 226-230.
11. Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14:570-576.
12. Levey AS, Stevens LA, Schmid CH, et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
13. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766-772.
14. Kidney Disease: Improving Global Outcomes (KDIGO)CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3:19-62.
15. Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27:1757-1772.
16. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-158.
17. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577-4583.
18. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3:e2942.
19. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW. Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab. 1975;41:339-345.
20. Urena P, Ferreira A, Morieux C, Drueke T, de Vernejoul MC. PTH/ PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant. 1996;11:2008-2016.
21. Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877-882.
22. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805-814.
23. Veverka V, Henry AJ, Slocombe PM, et al Characterisation of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009:M807994200.
24. Kusano E, Suzuki M, Asano Y, Itoh Y, Takagi K, Kawai T. Human α 1-microglobulin and its relationship to renal function. Nephron. 1985;41:320-324.
25. Flynn FV, Lapsley M, Sansom PA, Cohen SL. Urinary excretion of α 2-glycoprotein-1 (apolipoprotein H) and other markers of tubular malfunction in "non-tubular" renal disease. J Clin Pathol. 1992; 45:561-567.
26. Ekstrom B, Berggard I. Humanβ1-microglobulin. Purification procedure, chemical and physiochemical properties. J BiolChem. 1977; 252:8048-8057.
27. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Dev. 2007;10:84-96.
28. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics. 2010;9:2048-2062.
29. Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, et al. Atherosclerotic disease in type 2 diabetes is associated with an increase of sclerostin levels. Diabetes Care. 2013;36(6):1667-1674.